You are here:Home-Research Areas-Cancer-Ovarian Cancer

Request The Product List ofOvarian Cancer Ovarian Cancer

Cat. No. Product Name CAS No. Information
PC-61494

COTI-2

1039455-84-9

COTI-2 (COTI2) is an orally available thiosemicarbazone that may act on mutant forms of p53 and PI3K/AKT/mTOR pathway; induces apoptosis in a wide variety of human tumor cells in culture (IC50s<40 nM), inhibits the proliferation of colorectal cancer cell lines more effectively than cetuximab and erlotinib; shows superior activity against tumor, and is safe and well-tolerated in vivo.

Ovarian Cancer

Phase 1 Clinical

PC-60486

PTC-596

1610964-64-1

PTC-596 (PTC596) is a novel, orally active, small molecule inhibitor of BMI-1 that accelerates BMI-1 degradation, inhibits AML cells growth with IC50 of <100 nM; PTC-596 is a direct microtubule polymerization inhibitor; reduces total BMI-1 protein levels by 87% and 61% in MOLM-13 and OCI-AML3 cells at 100 nM, induces apoptosis and reduces the levels of ubiquitylated histone H2A; downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells.

Ovarian Cancer

Phase 1 Clinical

PC-60483

Pamiparib

1446261-44-4

Pamiparib (BGB-290, BGB290) is a highly potent, selective and brain penetrant PARP1/2 inhibitor with potent anti-tumor activity.

Ovarian Cancer

Phase 2 Clinical

PC-60186

Cridanimod

38609-97-1

Cridanimod (10-carboxymethyl-9-acridanone, 10-CMA, XBIO-101) is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route; displays extraordinary activity in phosphorylating IRF3 in the murine system; also increases progesterone receptor (PrR) expression in endometrial tissue.

Ovarian Cancer

Phase 2 Clinical

PC-42266

Triapine

143621-35-6

Triapine (3-AP, PAN-811, OCX191, NSC 663249) is a potent ribonucleotide reductase inhibitor with broad spectrum antitumor activity.

Ovarian Cancer

Phase 2 Clinical

PC-45909

Trabectedin

114899-77-3

Trabectedin (Ecteinascidin-743, ET-743, Ecteinascidin) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata that shows remarkably anticancer activity in a variety of in vitro and in vivo systems; a DNA minor groove, guanine-specific alkylating agent; shows hign potency against ovarian carcinoma xenografts.

Ovarian Cancer

Approved

PC-42681

MK-4827

1038915-60-4

MK-4827 (Niraparib, MK4827) is a highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2; inhibits PARP activity with EC50=4 nM in a whole cell assay, and inhibits proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10−100 nM range; well tolerated in vivo and demonstrates efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.

Ovarian Cancer

Approved

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com